Trial Profile
A Phase 1b Study of Ficlatuzumab, Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Intermediate or High Risk, Previously Untreated, Locally Advanced Head and Neck Squamous Cell Carcinoma With Biomarker Correlatives
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Ficlatuzumab (Primary) ; Cisplatin
- Indications Head and neck cancer
- Focus Adverse reactions
- 12 Sep 2016 Status changed from suspended to discontinued since the investigator left the institution
- 15 Jan 2016 Status changed from not yet recruiting to suspended, as reported by ClinicalTrials.gov.
- 31 Oct 2014 New trial record